Farmability and pharmability: Transforming the drug market to a health-and human rights-centred approach from self-cultivation to safe supply of controlled substances

Authors Fabian Pitter Steinmetz, Maja Kohek Published May 3, 2022 Background The supply chains addressing the global demand for major recreational drugs are hardly addressed due to international contracts, particularly the UN Single Convention on Narcotic Drugs. Currently applied regulatory changes have several disadvantages ranging from political tensions to the neglect of ecological aspects. The  …


Psilocybin Therapy for Treatment-Resistant Depression

Topline Results from COMPASS Pathways Phase IIb Trial   By Olivia Gorzynska In November 2021, COMPASS Pathways, a mental health care company, published a press release announcing results from its phase IIb trial on psilocybin therapy for treatment-resistant depression (TRD). Psilocybin is a naturally occurring psychedelic compound found in mushrooms of the Psilocybe genus. “Magic  …


Can psilocybin be safely administered under medical supervision? A systematic review of adverse event reporting in clinical trials

Authors Jeremy Roscoe, Olivia Lozy Published March 16, 2022 Psilocybin is a naturally occurring psychoactive chemical produced by various species of mushroom, mainly in the psilocybe genus. Human consumption of psilocybin, primarily for its psychoactive properties, dates back thousands of years (Tylš et al., 2013). It was first isolated in 1958 by Albert Hoffmann, who was later  …


Are psychedelics dangerous? - What the research says

Authors Anne K Schlag, Jacob Aday, Iram Salam, Jo C Neill, David J Nutt Published February 3, 2022 Psychedelic medicines are a rapidly developing area of clinical research and public health policy. Despite an increasing body of studies highlighting their efficacy to treat a broad range of medical conditions, psychedelic drugs remain a controversial issue  …


56. Microdosing with James Fadiman

 Who is James Fadiman? James Fadiman is a true man of many talents. Wikipedia calls him an ‘American writer’, but actually, he’s worked in multiple fields, from psychology, through to IT and, finally, to psychedelic research. He studied Psychology at Harvard University and obtained a PhD from Stanford University. As a graduate student at Stanford,  …


55. Right to Try Psychedelic Therapy with Spencer Hawkswell

 Access to Psilocybin-Assisted Psychotherapy This week’s episode features Spencer Hawkswell the CEO of TheraPsil – a non-profit coalition dedicated to helping Canadians in medical need access legal, psilocybin-assisted psychotherapy to treat end-of-life distress.  Spencer believes that responsible drug policy requires effective organization and leadership and is dedicated to bringing together the experts and advocates,  …


The Brain, Mind, and Ethics of Psychedelics - Q and A

A fascinating Q&A on the ethical and philosophical considerations in psychedelic science and explanations of the psychedelic experience.   Prof David Nutt David is a leading Neuroscientist and drug policy reform advocate. Formerly the Chief Drug Advisor to the UK government he is currently the Edmond J. Safra Professor of Neuropsychopharmacology and director of the  …


Working in Drug Science

In this webinar, you will learn about the medicalisation of both psychedelics and cannabis, from two of the biggest experts in these respective fields; Prof Jo Neill, and Prof Mike Barnes. We expect these industries to grow to tremendous size and want to prepare the next generation for a new economy of medicine and psychiatry.  …


Patient Perspective on Psychedelic Therapy - Q and A

A personal Q&A from two patients of psychedelic therapy:   Psilocybin for depression – Michael Bourne Michael Bourne is a 57-year-old website designer from the North East of England, who tried several unsuccessful depression treatments, including talking therapy and prescription medications, before turning to psilocybin clinical trials. Michael took part in research into psilocybin treatment  …


Ask the experts: Psilocybin and MDMA Research

In this webinar, two of the world’s leading psychedelic research experts; Dr Ben Sessa and Dr Meg Spriggs, answer questions on the therapeutic applications of MDMA and psilocybin!   Who is Dr Ben Sessa? Dr Ben Sessa is a consultant child and adolescent psychiatrist who has worked with young people and adults in the field  …


Are Psychedelics Legal in the Netherlands?

Psychedelic drugs in the Netherlands In the Netherlands, it’s not difficult to find a shop selling psychedelic drugs – magic truffles, cacti, 5-Meo-DMT, iboga, and the like are all widely available at ‘smart shops’. Retreat centers are also accessible within the country, where individuals can pay to trip in a safe environment, and undergo therapy  …


Psilocybin for OCD (Obsessive Compulsive Disorder)

Could psilocybin be used for the treatment of OCD? Psilocybin is currently being researched as a treatment for OCD by Drug Science founder, Prof David Nutt, at the Centre for Psychedelic Research. In this Drug Science webinar, Dr Nick Sireau provides an overview of OCD and the new research being launched into psilocybin as a  …


The World's Biggest Placebo-Controlled Microdosing Study

In this Drug Science webinar, Dr Balázs Szigeti explains the current science of microdosing as he presents the results from his self-blinded microdosing research, the largest placebo-controlled microdosing study in the world! Dr Szigeti also explains how participants created their microdoses with a placebo control as part of the revolutionary methodology he developed to reduce  …


YouGov Results - Is the UK Ready to Reschedule Psilocybin?

Summary Full Report Survey Data Does the UK support psilocybin research? Public perceptions of psilocybin-assisted therapy have been revealed in a new YouGov poll, commissioned by Drug Science. This is the first nationally representative poll of UK attitudes towards the medicalisation of psilocybin and support for policy changes (such as rescheduling psilocybin) to make this  …


Psychedelics and the Brain - In My Professional Opinion

In this Drug Science webinar, expert Neuropsychopharmacologist Professor David Nutt explains how psychedelic drugs such as psilocybin, LSD, DMT, and ayahuasca work in the human brain, and the applications for the treatment of mental health conditions such as depression, anxiety, and addiction. Prof Nutt outlines the history of psychedelic research, starting in the early 20th  …


Psychedelics and Nature Connection - In My Professional Opinion

There appears to be a growing disconnection between humans and their natural environments which has been linked to poor mental health and ecological destruction. Research shows that psychedelic usage is associated with enduring increases in nature connectedness. What makes psychedelics such as psilocybin promising agents for enhancing nature connectedness, and what are the potential implications  …


Psychological Support in Psilocybin Therapy - In My Professional Opinion

What is the role of psychological support in psychedelic treatments? In this webinar, Dr Sara Tai will explain why it is essential that psychedelic drugs such as psilocybin are administered in conjunction with psychotherapy. In such treatments, psychotherapy is primarily delivered at three distinct phases: Preparation for the psychedelic experience Guiding the psychedelic experience Integration  …


Psilocybin for Anorexia Nervosa

In this webinar, Dr Meg Spriggs explains the potential of psilocybin to treat anorexia nervosa, and offers valuable insights from the clinical trial investigating this application at the Centre for Psychedelic Research. Eating disorders are a complex mental health issue with few effective pharmaceutical treatments available. Meg provides an introductory background to some of the  …


Psilocybin Therapy for Depression - Clinical Insights

After the release of the first comparison of psilocybin with an SSRI antidepressant, Michelle Baker Jones & Leonie Schneider explain what psilocybin therapy for depression involves. Leonie was a patient of Michelle in psilodep 1, and together they provide insight into psilocybin therapy from the perspective of both therapist and patient. Michelle Baker Jones is  …


#34 - Psilocybin vs Antidepressants

 Psilocybin is being heralded as a major breakthrough in the fight against depression, but how does it compare to the most effective treatment that doctors prescribe for depression? This week’s episode features Dr Robin Carhart-Harris, a British neuroscientist who has led some of the most influential psychedelic studies to date. Professor Nutt and Robin  …


Women in Psychedelic Science - Part 3

The Contradictions of Ketamine: results from a new clinical trial treating alcohol use disorder – Prof Celia Morgan Celia Morgan is a Professor of Psychopharmacology and Head of Psychology at the University of Exeter. She started researching ketamine at UCL for her PhD with Val Curran over twenty years ago and branched out into research  …


Psilocybin Treatment for Depression - Clinical Insights

Psilocybin for depression is one of the most promising applications of psychedelic therapy. In particular, psilocybin therapy is being studied as an alternative to antidepressants in the treatment of treatment-resistant depression. In this Drug Science webinar, Dr Mourad Wahba explains the science behind psilocybin for depression, which is currently in clinical trials at a number  …


Psilocybin Treatment for Depression - Patient Perspective

Clinical trials are currently investigating psilocybin therapy, as a treatment for depression at research centres around the world. This webinar gives valuable insight into the benefits of psilocybin treatment, from the perspective of a patient who suffered from depression for most of his adult life. Michael Bourne is a 57-year-old website designer from the North  …


Psychedelic Microdosing - Just a Placebo Effect?

Authors: Balázs Szigeti, Laura Kartner, Allan Blemings, Fernando Rosas, Amanda Feilding, David J. Nutt, Robin L. Carhart-Harris, David Erritzoe Published: March 2, 2021 What is microdosing? Psychedelic microdosing involves consuming psychedelics such as LSD or psilocybin mushrooms at a microdose, which is typically about 10% of a recreational dose. Microdosing is gaining increasing popularity, with  …

2020 - The Year Of The Mushroom

By Dr Hannah Thurgur an Honorary Research Assistant for Drug Science As we welcome in the new year, Drug Science reflects on the year of 2020 for psilocybin research and celebrates these achievements. Here we focus on the use of psilocybin-assisted therapy in three different conditions to reflect the breadth of research currently taking place  …


Women in Psychedelic Science - Part 2

This is the second Women in Psychedelic Science symposium to showcase the ground-breaking and outstanding work of women in psychedelics. The symposium provides a clinical perspective of psychedelic therapy, as well as developments in psychedelic fieldwork.   Psychedelic therapy – Clinical trials: Dr Sara Tai  A clinical psychologist and expert in psychotherapy in clinical trials  …


Study Drug Sessions - Insights on psychedelic microdosing

Laura Kaertner – Insights on psychedelic microdosing Laura Kaertner is a research assistant at the Centre of Psychedelic Research at Imperial College London where she researches the effects of psychedelic microdosing. Her primary role is in the organisation and set-up of a large-scale observational microdosing study. Microdosing has gained significant media interest, with media reports  …


Clinical Insights - MDMA for Alcohol Use Disorder

Dr Ben Sessa – MDMA for Alcohol Use Disorder Dr Ben Sessa presents the first data from the open-label safety and tolerability proof of concept study exploring the potential role for 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy in treating patients with alcohol use disorder. At this stage, seven participants have completed the full 8-week MDMA-assisted psychotherapy treatment course,  …


2019: A year of expansion in psychedelic research, industry, and deregulation

Authors: Jacob S Aday, Emily K Bloesch, Christopher C Davoli Published: November 25, 2020 Public and scientific interest into psychedelic drugs has grown steadily over much of the last two decades, before an exponential increase in recent years. We contend that 2019, in particular, involved myriad notable changes in the science, industry, and deregulation of  …